Header Logo

Connection

CHAAN S NG to Adult

Back to Details
This is a "connection" page, showing publications CHAAN S NG has written about Adult.
CHAAN S NG
Connection Strength
0.591
Adult
  1. Risk of renal events following intravenous iodinated contrast material administration among inpatients admitted with cancer a retrospective hospital claims analysis. Cancer Imaging. 2018 Aug 24; 18(1):30.
    View in: PubMed
    Score: 0.024
  2. CT perfusion in normal liver and liver metastases from neuroendocrine tumors treated with targeted antivascular agents. Abdom Radiol (NY). 2018 07; 43(7):1661-1669.
    View in: PubMed
    Score: 0.024
  3. Utility of Intermediate-Delay Washout CT Images for Differentiation of Malignant and Benign Adrenal Lesions: A Multivariate Analysis. AJR Am J Roentgenol. 2018 08; 211(2):W109-W115.
    View in: PubMed
    Score: 0.024
  4. Differentiation of Malignant and Benign Adrenal Lesions With Delayed CT: Multivariate Analysis and Predictive Models. AJR Am J Roentgenol. 2018 Apr; 210(4):W156-W163.
    View in: PubMed
    Score: 0.023
  5. Combining Washout and Noncontrast Data From Adrenal Protocol CT: Improving Diagnostic Performance. Acad Radiol. 2018 07; 25(7):861-868.
    View in: PubMed
    Score: 0.023
  6. Observer Variability in CT Perfusion Parameters in Primary and Metastatic Tumors in the Lung. Technol Cancer Res Treat. 2018 01 01; 17:1533034618769767.
    View in: PubMed
    Score: 0.023
  7. CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clin Cancer Res. 2017 Jul 15; 23(14):3684-3691.
    View in: PubMed
    Score: 0.022
  8. Diagnostic performance of 18-F-FDG-PET-CT in adrenal lesions using histopathology as reference standard. Abdom Radiol (NY). 2017 02; 42(2):577-584.
    View in: PubMed
    Score: 0.022
  9. Effect on perfusion values of sampling interval of computed tomographic perfusion acquisitions in neuroendocrine liver metastases and normal liver. J Comput Assist Tomogr. 2015 May-Jun; 39(3):373-82.
    View in: PubMed
    Score: 0.019
  10. Effect of pre-enhancement set point on computed tomographic perfusion values in normal liver and metastases to the liver from neuroendocrine tumors. J Comput Assist Tomogr. 2014 Jul-Aug; 38(4):526-34.
    View in: PubMed
    Score: 0.018
  11. Metastases to the liver from neuroendocrine tumors: effect of duration of scan acquisition on CT perfusion values. Radiology. 2013 Dec; 269(3):758-67.
    View in: PubMed
    Score: 0.017
  12. Effect of duration of scan acquisition on CT perfusion parameter values in primary and metastatic tumors in the lung. Eur J Radiol. 2013 Oct; 82(10):1811-8.
    View in: PubMed
    Score: 0.017
  13. Effect of sampling frequency on perfusion values in perfusion CT of lung tumors. AJR Am J Roentgenol. 2013 Feb; 200(2):W155-62.
    View in: PubMed
    Score: 0.017
  14. Reproducibility of perfusion parameters obtained from perfusion CT in lung tumors. AJR Am J Roentgenol. 2011 Jul; 197(1):113-21.
    View in: PubMed
    Score: 0.015
  15. Semiautomated motion correction of tumors in lung CT-perfusion studies. Acad Radiol. 2011 Mar; 18(3):286-93.
    View in: PubMed
    Score: 0.015
  16. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR Am J Roentgenol. 2011 Mar; 196(3):569-76.
    View in: PubMed
    Score: 0.015
  17. Effect of IV contrast medium on renal function in oncologic patients undergoing CT in ICU. AJR Am J Roentgenol. 2010 Aug; 195(2):414-22.
    View in: PubMed
    Score: 0.014
  18. Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol. 2010 Feb; 194(2):W134-40.
    View in: PubMed
    Score: 0.013
  19. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. AJR Am J Roentgenol. 2010 Jan; 194(1):166-71.
    View in: PubMed
    Score: 0.013
  20. Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study. J Comput Assist Tomogr. 2009 May-Jun; 33(3):460-5.
    View in: PubMed
    Score: 0.013
  21. Beyond the three P's: adrenal involvement in MEN1. Endocr Relat Cancer. 2024 Feb 01; 31(2).
    View in: PubMed
    Score: 0.009
  22. Evaluation of early abdominopelvic computed tomography in patients with acute abdominal pain of unknown cause: prospective randomised study. BMJ. 2002 Dec 14; 325(7377):1387.
    View in: PubMed
    Score: 0.008
  23. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021 04; 9(4).
    View in: PubMed
    Score: 0.007
  24. Diagnostic performance of adrenal CT in the differentiation of adenoma and pheochromocytoma. Acta Radiol. 2020 Aug; 61(8):1080-1086.
    View in: PubMed
    Score: 0.007
  25. A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas. 2019 03; 48(3):381-386.
    View in: PubMed
    Score: 0.006
  26. Operation duration and adrenal gland size, but not BMI, are correlated with complication rate for posterior retroperitoneoscopic adrenalectomy for benign diseases. Surgery. 2019 03; 165(3):637-643.
    View in: PubMed
    Score: 0.006
  27. Conditional survival of patients with small renal masses undergoing active surveillance. BJU Int. 2019 03; 123(3):447-455.
    View in: PubMed
    Score: 0.006
  28. CT and 18F- FDG-PET-CT Findings in Secondary Adrenal Lymphoma with Pathologic Correlation. Acad Radiol. 2019 06; 26(6):e108-e114.
    View in: PubMed
    Score: 0.006
  29. Contrast-associated acute kidney injury in the critically ill: systematic review and Bayesian meta-analysis. Intensive Care Med. 2017 Jun; 43(6):785-794.
    View in: PubMed
    Score: 0.005
  30. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol. 2016 05; 77(5):973-7.
    View in: PubMed
    Score: 0.005
  31. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74.
    View in: PubMed
    Score: 0.005
  32. Visual Vignette. Endocr Pract. 2015 Jul; 21(7):854.
    View in: PubMed
    Score: 0.005
  33. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas. 2015 Mar; 44(2):190-7.
    View in: PubMed
    Score: 0.005
  34. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Apr; 75(4):869-74.
    View in: PubMed
    Score: 0.005
  35. Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 2014 Nov 15; 5(21):10280-92.
    View in: PubMed
    Score: 0.005
  36. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int. 2014 Jun; 113(6):871-7.
    View in: PubMed
    Score: 0.005
  37. Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. World J Surg. 2014 Jun; 38(6):1318-27.
    View in: PubMed
    Score: 0.005
  38. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int. 2014 Mar; 113(3):376-82.
    View in: PubMed
    Score: 0.004
  39. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol. 2013 Oct; 36(5):450-4.
    View in: PubMed
    Score: 0.004
  40. Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J Am Coll Surg. 2013 Feb; 216(2):280-9.
    View in: PubMed
    Score: 0.004
  41. A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res. 2012 Aug; 22(4):294-301.
    View in: PubMed
    Score: 0.004
  42. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012 Dec; 62(6):1013-9.
    View in: PubMed
    Score: 0.004
  43. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol. 2012 Apr; 198(4):902-8.
    View in: PubMed
    Score: 0.004
  44. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res. 2012 Feb 15; 18(4):1120-8.
    View in: PubMed
    Score: 0.004
  45. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother. 2012 Jan; 35(1):66-72.
    View in: PubMed
    Score: 0.004
  46. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol. 2011 Dec; 197(6):W992-W1000.
    View in: PubMed
    Score: 0.004
  47. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol. 2011 Nov; 12(12):1109-17.
    View in: PubMed
    Score: 0.004
  48. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011 Sep 15; 17(18):6052-60.
    View in: PubMed
    Score: 0.004
  49. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
    View in: PubMed
    Score: 0.004
  50. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther. 2011 Jul; 10(7):1300-7.
    View in: PubMed
    Score: 0.004
  51. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. Clin Colorectal Cancer. 2010 Dec; 9(5):311-4.
    View in: PubMed
    Score: 0.004
  52. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. Cancer. 2010 Sep 01; 116(17):4086-94.
    View in: PubMed
    Score: 0.004
  53. Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer. 2011 Jan 01; 117(1):77-85.
    View in: PubMed
    Score: 0.004
  54. Small increases in serum creatinine are associated with prolonged ICU stay and increased hospital mortality in critically ill patients with cancer. Support Care Cancer. 2011 Oct; 19(10):1527-32.
    View in: PubMed
    Score: 0.003
  55. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1087-93.
    View in: PubMed
    Score: 0.003
  56. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol. 2010 Jan; 65(2):235-41.
    View in: PubMed
    Score: 0.003
  57. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8.
    View in: PubMed
    Score: 0.003
  58. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs. 2010 Oct; 28(5):634-40.
    View in: PubMed
    Score: 0.003
  59. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2009 Jun; 64(1):161-7.
    View in: PubMed
    Score: 0.003
  60. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008 Jul 15; 14(14):4491-9.
    View in: PubMed
    Score: 0.003
  61. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery. 2007 Dec; 142(6):867-75; discussion 867-75.
    View in: PubMed
    Score: 0.003
  62. CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. AJR Am J Roentgenol. 2007 Aug; 189(2):378-85.
    View in: PubMed
    Score: 0.003
  63. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007 Jun 10; 25(17):2369-76.
    View in: PubMed
    Score: 0.003
  64. Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol. 2007 May; 188(5):1307-12.
    View in: PubMed
    Score: 0.003
  65. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007 Jan; 14(1):14-24.
    View in: PubMed
    Score: 0.003
  66. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer. 2006 Nov 01; 107(9):2254-61.
    View in: PubMed
    Score: 0.003
  67. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol. 2006 Jun 20; 24(18):2858-65.
    View in: PubMed
    Score: 0.003
  68. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol. 2006 Mar 01; 24(7):1145-51.
    View in: PubMed
    Score: 0.003
  69. Refractory Hodgkin lymphoma responds to pentostatin (2'-deoxycoformycin). Leuk Lymphoma. 2006 Feb; 47(2):373-5.
    View in: PubMed
    Score: 0.003
  70. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol. 2005 Aug 20; 23(24):5464-73.
    View in: PubMed
    Score: 0.002
  71. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol. 2004 May 15; 22(10):1815-22.
    View in: PubMed
    Score: 0.002
  72. Diagnostic value of Doppler assessment of the hepatic and portal vessels and ultrasound of the spleen in liver disease. Eur J Gastroenterol Hepatol. 2004 Feb; 16(2):147-55.
    View in: PubMed
    Score: 0.002
  73. Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors. Cancer. 2003 Oct 01; 98(7):1457-64.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.